Cassava Sciences Inc vs Solaredge Technologies Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Solaredge Technologies Inc trades at $31.87 (market cap $2.00B). The key difference: Solaredge Technologies Inc is far larger — about 50.8× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 2,739,860). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Solaredge Technologies Inc for 34 Days on average.
| FLNA | SEDG | |
|---|---|---|
Market Cap | $39.40M | $2.00B |
Volume | 759,018 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $4.64 | $78.51 |
52-Week Low | $0.68 | $28.47 |
Typical Hold Time | 37 Days | 34 Days |
Enterprise Value | -$43.28M | $1.86B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $405.45 million in 2025, with a negative net margin of -34.24%, though revenue improved to $1.18 billion. Recent news highlights an ongoing fraud investigation by Pomerantz Law Firm and ambitious long-term revenue targets of $2.4 billion by 2029, alongside new AI data center initiatives developed with NVIDIA.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests modest upside with a $37.75 price target. Key risks include execution on growth targets, competitive pressures, and macroeconomic headwinds affecting solar project financing. Institutional sentiment is cautious, with 56.25% hold ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →